🚀 VC round data is live in beta, check it out!
Kanaph Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kanaph Therapeutics and similar public comparables like Clinuvel Pharmaceuticals, Immuneering, Monopar Therapeutics, Silence Therapeutics and more.
Kanaph Therapeutics Overview
About Kanaph Therapeutics
Kanaph Therapeutics Inc is a biotech company dedicated to developing anticancer drugs and ophthalmic disease treatments based on human genome-based drug development technology. Its core technology lies in identifying novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and in developing drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and synthetic drugs, based on these findings. The groups pipeline products are KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701.
Founded
2019
HQ
Employees
24
Website
Sectors
Financials (FY)
EV
$333M
Kanaph Therapeutics Stock Performance
Kanaph Therapeutics has current market cap of $339M, and enterprise value of $333M.
Kanaph Therapeutics' stock price is $26.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $333M | $339M | 1.4% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKanaph Therapeutics Valuation Multiples
Kanaph Therapeutics Financial Valuation Multiples
As of April 30, 2026, Kanaph Therapeutics has market cap of $339M and EV of $333M.
Equity research analysts estimate Kanaph Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $339M | XXX | $339M | XXX | XXX | XXX |
| EV (current) | $333M | XXX | $333M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kanaph Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kanaph Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kanaph Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinuvel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Immuneering | XXX | XXX | XXX | XXX | XXX | XXX |
| Monopar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Silence Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tanvex BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kanaph Therapeutics M&A Activity
Kanaph Therapeutics acquired XXX companies to date.
Last acquisition by Kanaph Therapeutics was on XXXXXXXX, XXXXX. Kanaph Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kanaph Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKanaph Therapeutics Investment Activity
Kanaph Therapeutics invested in XXX companies to date.
Kanaph Therapeutics made its latest investment on XXXXXXXX, XXXXX. Kanaph Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kanaph Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kanaph Therapeutics
| When was Kanaph Therapeutics founded? | Kanaph Therapeutics was founded in 2019. |
| Where is Kanaph Therapeutics headquartered? | Kanaph Therapeutics is headquartered in South Korea. |
| How many employees does Kanaph Therapeutics have? | As of today, Kanaph Therapeutics has over 24 employees. |
| Is Kanaph Therapeutics publicly listed? | Yes, Kanaph Therapeutics is a public company listed on Korea Exchange. |
| What is the stock symbol of Kanaph Therapeutics? | Kanaph Therapeutics trades under 0082N0 ticker. |
| When did Kanaph Therapeutics go public? | Kanaph Therapeutics went public in 2026. |
| Who are competitors of Kanaph Therapeutics? | Kanaph Therapeutics main competitors are Clinuvel Pharmaceuticals, Immuneering, Monopar Therapeutics, Silence Therapeutics. |
| What is the current market cap of Kanaph Therapeutics? | Kanaph Therapeutics' current market cap is $339M. |
| Is Kanaph Therapeutics profitable? | No, Kanaph Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.